US equities |
MU $910.66 ▼-0.38% NVDA $217.30 ▼-1.81% SNDK $1,338.90 ▼-4.59% SPCX $146.65 ▼-3.62% AMD $549.27 ▼-3.78% INTC $94.08 ▼-4.12% AAPL $344.28 ▲+0.38% TSM $419.59 ▼-2.42%
FinancialContent

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

59.88 +0.89 (+1.51%)
Delayed Quote Updated: 1:31 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Royalty Pharma PLC (NASDAQ:RPRX) Exceeds Q2 2025 Earnings Estimates and Raises Full-Year Guidance ↗
Royalty Pharma (RPRX) beats Q2 2025 earnings with $727M revenue, up 20% YoY, driven by key therapies. Shares rise as company raises full-year guidance, reinforcing growth confidence. 
Via Chartmill
News headline image
Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue Estimates
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.8% year on year to $579 million. Its GAAP profit of $0.16 per... 
Via StockStory
News headline image
Royalty Pharma Reports Second Quarter 2025 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings To Watch: Royalty Pharma (RPRX) Reports Q2 Results Tomorrow
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be announcing earnings results this Wednesday before the bell. Here’s what to look for. 
Via StockStory
Topics Government World Trade
News headline image
A Look Into Royalty Pharma Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Royalty Pharma? ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
2 Reasons to Watch RPRX and 1 to Stay Cautious
Royalty Pharma has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.3%. The stock now trades at $36.72, marking a 16.2% gain. This was partly thanks to its... 
Via StockStory
Topics Stocks
News headline image
3 Profitable Stocks to Research Further
Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance profitability with reinvestment, setting... 
Via StockStory
Topics Supply Chain
News headline image
Royalty Pharma Declares Third Quarter 2025 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
2 Surging Stocks to Research Further and 1 to Be Wary Of
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
News headline image
Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds ↗
Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch. 
Via Benzinga
News headline image
Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma ↗
Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured... 
Via Stocktwits
News headline image
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $568.2 million. Its non-GAAP EPS of $1.06 per share was... 
Via StockStory
News headline image
2 Value Stocks to Target This Week and 1 to Turn Down
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
News headline image
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
1 Stock Under $50 with Competitive Advantages and 2 to Question
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Royalty Pharma Completes the Acquisition of Its External Manager
From Royalty Pharma plc
Via GlobeNewswire
News headline image
3 of Wall Street’s Favorite Stocks with Mounting Challenges
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $568 million. Its GAAP profit of $0.75 per share... 
Via StockStory
News headline image
Royalty Pharma Reports First Quarter 2025 Results
From Royalty Pharma plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >